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Purpose: To describe the clinical findings and genetic analysis in two brothers having a novel retinal disease characterized
by an enhanced S-cone phenotype with normal rod function.
Methods:  Both  patients  underwent  complete  ophthalmologic  examinations,  including  fundus  photography,
electroretinography (ERG), fluorescein angiography and optical coherence tomography (OCT). Mutation analysis of the
following candidate genes was performed: nuclear receptor subfamily 2 group E member 3 (NR2E3), neural retina leucine
zipper (NRL), nuclear receptor subfamily 1 group D member 1 (NR1D1), and thyroid hormone receptor beta (THRB).
Results: Spectral photopic ERG responses demonstrated enhanced S-cone function in both patients. Their scotopic b-
wave ERG amplitude responses, however, were within normal limits. Their scotopic a-wave amplitude responses were
within the lower limit of normal. The a- and b-wave latencies were normal for one sibling and on the upper limit of normal
for the other. Peripheral retinal findings were normal. OCT showed flattening of the macular curvature and thinning of
the photoreceptor layer. Mutation analysis of NR2E3, NRL, NR1D1, and THRB genes was negative.
Conclusions: We describe what appears to be a previously unidentified familial retinal phenotype with enhanced S-cone
function and well preserved rod system function in contrast to the severely reduced rod function seen in the enhanced S-
cone syndrome (ESCS). Genetic analysis of candidate genes did not reveal the cause of disease. We postulate that the
disease might be caused by mutation of another, as yet unidentified gene, which encodes a protein that functions as a
negative inhibitor of rod and S-cone development.
The  sensitive  short-wavelength  cones  (S-cones)
comprise about 10% of the cone population in the adult human
retina [1]. They differ from the sensitive long- and medium-
wavelength cones (L- and M-cones, respectively) in function,
anatomy,  and  retinal  distribution  [1,2].  Enhanced  S-cone
syndrome  (ESCS)  is  a  rare  autosomal  recessive  disorder
characterized by severely reduced function of rods, L cones
and  M  cones,  with  enhanced  S-cone  function.  Other
characteristics are night blindness, cystoid maculopathy, and
degenerative changes of the vascular arcades [3,4].
Full-field  spectral  (white  and  chromatic)
electroretinogram  (ERG)  findings  have  shown  that  while
patients with ESCS have severely reduced L- and M- cone
responses, they show hypersensitive responses of the S-cones
[5,6]. In addition, scotopic responses are severely diminished
as a consequence of rod system involvement as well. Single-
flash  photopic  responses,  mediated  by  S-cones  only,  are
within normal limits. The retinas of patients with ESCS are
occupied by a larger than normal population of S-cones, which
replace many of the rods and the L- and M-cones [7]. These
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S-cones are responsible for the normal or near-normal single-
flash photopic ERG responses. Mutations in the photoreceptor
cell-specific nuclear receptor subfamily 2 group E member 3
gene NR2E3, which is mapped to chromosome 15q24 and
plays a role in photoreceptor differentiation and development,
are found in a large majority of patients with ESCS [8].
We report a novel retinal phenotype in two adult siblings
within  an  Arab  family  showing  a  typical  ESCS  photopic
response  on  ERG  but  relatively  normal  scotopic  ERG
responses and normal retinal peripheral appearance. To the
best of our knowledge, this particular set of symptoms has not
been previously reported.
METHODS
Patients: Two of ten adult siblings from an Arab family with
consanguineous parents (first-order cousins) were studied.
Both patients reported having reduced central vision, impaired
color vision, and photophobia since childhood, but did not
complain of impaired night vision. Patient 1 (P1) was a 45-
year-old  male  who  came  to  our  outpatient  clinic  (Sheba
Medical Center) complaining that over the past 5 years his
vision had deteriorated. On admission to the clinic his best
corrected visual acuity (BCVA) in both eyes was 1/20 with
correction of −5.0 diopters. His 41-year-old brother, patient 2
(P2), also came to our clinic, complaining that his vision had
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2241deteriorated over the past 7 years. His BCVA on admission
was 20/180 in the right eye and 20/600 in the left eye with
correction of −7.0 diopters in both eyes. The medical histories
of both brothers were otherwise unremarkable.
Both patients participated in the study after signing their
informed consent to a protocol that was approved by the
Institutional  Review  Board  (Sheba  Medical  Center,  Tel
Hashomer, Israel). This study was approved by the review
board of the Sheba Medical Center. This study conformed to
the  tenets  of  the  Declaration  of  Helsinki  and  ARVO’s
statements on human patients.
Clinical  studies:  Ophthalmological  examinations  included
BCVA,  slit-lamp  and  dilated  fundus  examination,  fundus
photography,  ERG,  fluorescein  angiography,  and  optical
coherence tomography (OCT). The patients had been referred
by their general eye practitioner in Umm al-Fahm, Israel.
Full-field ERG scans were obtained from both eyes of
each patient by following the protocol of the International
Society for Clinical Electrophysiology of Vision (ISCEV)
[9]. After application of tropicamide 1% and phenylephrine
10% drops, the diameter of the dilated pupil was measured
and the patient was dark-adapted for 30 min. A bipolar Burian-
Allen electrode contact lens was placed in each eye. Scotopic
responses  were  recorded  for  four  single  flash  stimulus
increment light intensities (0.023 cd-s/m2, 2.44 cd-s/m2, 23.5
cd-s/m2, and 252 cd-s/m2). For testing of photopic responses,
the  patient  was  then  light-adapted  for  10  min  in  white
background light (29.63 cd/m2) before being exposed to a
single white flash stimulus (2.44 cd-s/m2) and white 30-Hz
flicker  (2.44  cd-s/m2).  Light-adapted  spectral  ERGs  were
recorded using a handheld full-field stimulator (Color Mini-
Ganzfeld  Stimulator  [Kurbisfeld],  LKC  Technologies,
Gaithersburg,  MD)  powered  by  colored  light-emitting
devices. Responses were evoked by red (627 nm), green (530
nm), and blue (470 nm) stimuli.
Stratus OCT 3 (Humphrey Instruments, Zeiss, Dublin,
CA; version 4.0.1) scans were performed after pupils were
dilated using macular thickness protocols and line scans at 0°,
25°, 90° and 125° at 6-mm and 9-mm lengths.
Molecular genetic analyses: Genomic DNA was obtained
from peripheral blood lymphocytes using the FlexiGene DNA
kit (Qiagen). The direct sequencing method was applied for
screening  of  coding  exons  as  well  as  of  flanking  intron
sequences of the NR2E3, neural retina leucine zipper NRL,
thyroid hormone receptor beta THRB, and nuclear receptor
subfamily 1 group D member 1 NR1D1 genes. Amplification
by PCR was conducted as previously described [10]. Primer
sequences used to amplify the genomic fragments are listed
in Table 1.
RESULTS
In both patients, ophthalmic slit-lamp biomicroscopy revealed
no lens opacity or degenerative vitreous changes in either eye.
Fundus examination in both brothers demonstrated bilateral
cystoid-like  macular  lesions  with  no  pigmentary  changes
(Figure 1A demonstrates fundus findings in P1). Fluorescein
angiography showed no leakage in the macula in either of the
brothers.
OCT of the macular area showed loss both of normal
neuroretinal contours and of normal neuroretinal architecture.
The  photoreceptor  layer  showed  severe  thinning  in  the
macular area (Figure 1B).
Full-field scotopic ERG responses showed a- and b-wave
amplitudes  and  latencies  within  the  normal  range
(assessments of amplitude and latency for both a- and b-waves
were based on ERG responses from 100 normal eyes). The a-
wave amplitude was smaller in P1, but was within the lower
limit of normal. The a-wave and the b-wave latencies were
longer  for  both  waves  but  within  the  upper  normal  limit
(Figure  2).  Photopic  30-Hz  flicker  ERG  responses  were
absent. Photopic spectral ERG responses evoked by a blue
(440–480 nm 50% pass) stimulus (2.44 cd-s/m2) revealed b-
wave amplitudes of 97 µV and 63 µV for the right and left
eye, respectively, In P1 and of 62 µV and 67 µV, respectively,
in P2 (compared to 11±3 µV in the control). In contrast, b-
wave  amplitudes  could  not  be  detected  in  spectral  ERG
responses evoked by a red (510–580 nm 50% pass) stimulus
(2.44  cd-s/m2).  Response  amplitudes  and  implicit  times
measured for the white stimuli were similar to those obtained
for the responses to blue stimuli (Figure 2).
Mutation  analysis  of  P1  was  performed  by  direct
sequencing of the following PCR-amplified exons: NR2E3
(exons  1–8),  NRL  (exons  1–3),  THRB  (retinal-specific
transcripts: exons 1 and 4–11), and NR1D1 (exons 1–8). No
potentially pathogenic mutations were detected in the coding
region  or  in  the  exon/intron  boundaries  of  these  genes;
however,  the  possibility  of  a  mutation  in  the  non-coding
regions cannot be ruled out. The following nonpathogenic
changes were identified: in NR1D1: the known homozygous
single nucleotide polymorphism IVS5+40G>T (rs72836608)
and a novel sequence change, IVS5–12_13insA; in THRB, a
silent  heterozygous  sequence  change  was  observed  at
rs3752874.
DISCUSSION
Based on the spectral photopic ERG responses observed in
two Arab siblings with parental consanguinity, we diagnosed
enhanced S-cone activity with higher than normal S-cone
response and undetectable L-cone response. The photopic
ERG responses seen in our patients resembled those seen in
ESCS. However, unlike ESCS patients, who show marked
peripheral  pigment  clumping,  our  patients  had  none.
Moreover,  the  severely  reduced  scotopic  ERG  responses
typical of ESCS patients [3,4] were not seen in our patients:
scotopic  b-wave  amplitudes  in  both  brothers  were  within
normal limits and scotopic a-wave amplitude responses were
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2242TABLE 1. PRIMERS USED TO AMPLIFY CANDIDATE GENES FOR THE NEW RETINAL PHENOTYPE DEMONSTRATING ENHANCED S-CONE FUNCTION WITH
PRESERVED ROD FUNCTION: THE NUCLEAR RECEPTOR SUBFAMILY 2 GROUP E MEMBER 3 (NR2E3), NEURAL RETINA LEUCINE ZIPPER (NRL), THYROID
HORMONE RECEPTOR BETA (THRB) AND NUCLEAR RECEPTOR SUBFAMILY 1 GROUP D MEMBER 1 (NR1D1) GENES.
Primer name Gene Exon Sequence 5′-3′ PCR product size
NR2E3–1F NR2E3 1 CAGGCCTCCCGCAGGCAGGCAG 242
NR2E3–1R NR2E3 1 CCATGGTCCCTGCGAACCTC  
NR2E3–2F NR2E3 2 GAGGGGAGCGTGCAGCCCTG 248
NR2E3–2R NR2E3 2 CACCCCTCCAGAACCCCTCAG  
NR2E3–3F NR2E3 3 GTCCAAGCCCATGGCTCAGG 242
NR2E3–3R NR2E3 3 GAAGGGTCAGGACGACACGC  
NR2E3–4F NR2E3 4 GGGAGGTGACAAGAAATGGGC 327
NR2E3–4R NR2E3 4 GAAGCCAAGCCCTGCTGTGC  
NR2E3–5F NR2E3 5 CAAGTACTCCCTGCCACCTC 316
NR2E3–5R NR2E3 5 GTGCCCTGTCTGGTTGACTC  
NR2E3–6F NR2E3 6 GCTGTGTGTCTGCCATAACA 316
NR2E3–6R NR2E3 6 CTCAAGGTTTGGGCAGAGAC  
NR2E3–7F NR2E3 7 CTGTGCTAAGCTCACTGGTG 183
NR2E3–7R NR2E3 7 GAGGTCAGGGACAGATGAGTG  
NR2E3–8F NR2E3 8 GTCGTAAAACTGATGGCGTCCTC 232
NR2E3–8R NR2E3 8 GCAAATGTTTCGTTTCAGTAGATTG  
NRL-1F NRL 1 CACAGATGACCTCAGAGAGCTGGCCCTTTA 237
NRL-1R NRL 1 CAGGTGTTAAAGAGGGGGTTCTAGGTGAGC  
NRL-2F NRL 2 ACCATCCCTCTGGCTTTCCAAACTCTTGCT 683
MRL-2R NRL 2 GATCTGATTGCTTTCAAGGGACCTTCTCCC  
NRL-3F NRL 3 GACCTGGCGCTGACCCGGTTTCTGCATTCT 429
NRL-3R NRL 3 GCCACCCCCACCAGCCCCCACTACACCACA  
THRB-1F THRB 1 TGGAGAATGCATGCGTAGAC 439
THRB-1R THRB 1 CGAAAACAAACAGTGAAACTTTG  
THRB-4F THRB 4 AATGCATATGATATTGTTTGGAAC 264
THRB-4R THRB 4 GGTTTGGAAATAACGGTTGC  
THRB-5F THRB 5 CTTGCCTTCCAAAACTCTGC 261
THRB-5R THRB 5 CACCATACATTGGAAGAGAAATG  
THRB-6F THRB 6 TCTGGCCTAGCAACCTTAGC 101
THRB-6R THRB 6 ACTGGGAGGGGACTGGAG  
THRB-7F THRB 7 AGGTCCAAAACGATTCATCTC 148
THRB-7R THRB 7 CCCAGTCGATCTCCTTGAAC  
THRB-8F THRB 8 TTGCTGTGTATCTTGGGAGC 206
THRB-8R THRB 8 TCCCAAGGTGATGAGGACTG  
THRB-9F THRB 9 TTCAGAAGAGATTTTCTGCCAC 147
THRB-9R THRB 9 TCGTTTTGTACTGACGTTGC  
THRB-10F THRB 10 CAAATGTTAATCACAGAAGGTTATTCC 259
THRB-10R THRB 10 AGCGCTAGACAAGCAAAAGC  
THRB-11F THRB 11 ATTGGACAAAGCAAGCCTTC 242
THRB-11R THRB 11 TGGAATGAAATGACACCCAG  
NR1D1–1F NR1D1 1 TCTCTCTGCTCTTCCCATGC 361
NR1D1–1R NR1D1 1 CACCCCAGTCCCTTACAAAG  
NR1D1–2F NR1D1 2 GCTCCACATGGTGAACTGAG 553
NR1D1–2R NR1D1 2 GTCCTGGCAAGACTGGTGTC  
NR1D1–3–4F NR1D1 40606 CTTTTCCCTCCCTGGATCTC 532
NR1D1–3–4R NR1D1 40606 CAGTATGATGTGTCTCCATTTGTG  
NR1D1–5F NR1D1 5 GTGAAACCCCAAGCCTTCAG 850
NR1D1–5F NR1D1 5 CACACTCAGCCTCCAGGAAC  
NR1D1–6F NR1D1 6 CATCCTTCAGGGCCACAG 390
NR1D1–6F NR1D1 6 AGATCGCACCATTGCACTC  
NR1D1–7F NR1D1 7 TTCAGAAACAACCCCCACTC 345
NR1D1–7F NR1D1 7 CCTACCTGCAGAGACAAGCAC  
NR1D1–8F NR1D1 8 CAGGGAGAGGCTGCATTG 392
NR1D1–8R NR1D1 8 TGGTTTGCTTTTCCTTTTCG  
Primers used to amplify candidate genes for the new retinal phenotype with enhanced S-cone function with preserved rod
function: the NR2E3, neural retina leucine zipper (NRL), thyroid hormone receptor beta (THRB) and nuclear receptor subfamily
1 group D member 1 (NR1D1) genes.
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2243Figure 1. A: Fundus photography of patient 1 (P1) demonstrating bilateral cystoid-like macular lesions. There are no pigmentary changes.
B: Optical coherence tomography (OCT) scans through the macular region of P1 (upper part) and P2 (lower part). There is loss of foveal
contour (asterisks) and thinning of the hyporeflective layer representing the photoreceptors in the macular region (white arrows). P1 and P2
scans are off-center, but foveas can be seen. C: Reference areas within an OCT through the macular region of a normal patient. GCL, Ganglion
cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; NFL, nerve fiber layer; OPL, outer plexiform layer; RPE, retinal pigment
epithelium.
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2244found to be within the lower limit of normal with latencies
within  the  upper  normal  limit.  The  somewhat  borderline
scotopic a-wave findings in our patients can be attributed to a
slow a-wave composed of rods and S-cones without L- or M-
cones. Moreover, it could be postulated that generation of the
consecutive positive component of the ERG (the b-wave)
prevented  continuation  of  the  relatively  slower  a-wave,
resulting in a smaller a-wave. Further support for a new entity
comes from the absence of peripheral retinal pathology and
remarkable differences between the photopic and scotopic
responses  to  high-intensity  stimulus  (unlike  patients  with
ESCS,  who  show  nearly  identical  photopic  and  scotopic
responses  [4]).  Last,  the  negative  results  obtained  on
screening  of  candidate  genes,  including  NR2E3,  for
pathological mutations also support a new entity.
The phenotype described in this study appears to reflect
a  new  ocular  genetic  disease  which,  to  the  best  of  our
knowledge, has never before been documented. Wright et al.
[11] described one patient (“Patient A”) who was diagnosed
with  ESCS  and  exhibited  some  features  resembling  the
phenotype  that  we  describe  here.  However,  whereas  rod
function in our patients was within the normal range, “Patient
Figure  2.  Electroretinograms  from
patient  1  (P1)  and  patient  2  (P2)
compared  to  a  normal  subject.  A:
Photopic responses. No responses to red
stimuli can be detected, whereas white
stimuli show responses that are mostly
within normal limits. Amplitudes of the
response to blue stimuli are markedly
higher than in normal subjects. Photopic
30-Hz flicker ERG responses are absent.
Isolated  rod  b-wave  amplitudes  and
maximal responses are generally within
the normal limits (see B). B: Plots of
scotopic response intensities from both
patients. ERG intensities are shown as
logarithmic values of stimulus intensity.
P1 and P2 are represented in red and
blue  lines,  respectively  (one  line  for
each  eye).  Black  and  Vertical  lines
represent the normal average and range
from 100 normal eyes, respectively. As
this parameter does not follow a normal
(Gaussian)  distribution  but  is  skewed
[15,16], to obtain the normal range the
values  were  first  converted  to  their
log10  values,  which  normalizes  the
distribution. Mean values±2.5 standard
deviations  (SD)  were  then  calculated
and the values were converted back to
their  antilog  values.  The  a-wave
amplitudes  (left)  are  generally  within
the lower normal limit (except for P1 at
the lowest ERG intensity, where it is
lower  than  normal).  The  b-wave
amplitudes  (right)  are  within  normal
limits at all light intensities tested. C:
Latency plots of the scotopic responses
from both patients. For normal values,
the normal range was calculated as the
mean±2.5  SD.  The  a-wave  latencies
(left) are within normal limits (except
for  P1  at  the  lowest  ERG  intensity,
where it is longer than normal). The b-
wave  latencies  (right)  are  within  the
normal  limits  at  all  intensities,  other
than in P1 at 2.44 cd-s/m2 (log=0.39).
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2245A” showed a unique clinical feature of moderate rod function
in addition to pigment clumps at the retinal vascular arcades,
which were not seen in our patients. “Patient A” also had no
detectable mutation in the NR2E3 gene, and it was suggested
that the cause of his disease might be a digenic mechanism
with a heterozygous NRL mutation and a mutation in another,
unknown gene.
We attempted to identify the underlying molecular defect
in our patients by analyzing the NR2E3 gene, mutation of
which is the classical cause of ESCS. No pathogenic mutation
was detected. Bearing in mind the abovementioned suggestion
of a heterozygous mutation with a digenic mechanism [11] we
also analyzed NRL, but again found no pathogenic mutations.
NRL forms part of a transcription regulatory complex with
NR1D1 in vivo and synergistically activates the expression of
rhodopsin. Two nonpathogenic homozygous changes were
identified  in  NR1D1,  but  no  pathogenic  mutations  were
identified. Another related gene, THRB, was also excluded as
the cause of disease in this family.
In their attempt to understand the molecular genetics of
photoreceptor development, Bumsted O’Brien et al. showed
that loss of NR2E3 function in rd7 mice was associated with
an increased number of S-cones, suggesting that NR2E3 may
function  as  a  suppressor  of  S-cone  differentiation  [12].
Another  transcription  factor  essential  for  photoreceptor
differentiation is the NRL gene, which is expressed in rods but
not in cones [2]. In humans, missense mutations in NRL are
associated  with  autosomal  dominant  retinitis  pigmentosa
[13]. In mice, targeted deletion of NRL (NRL−/−) results in a
complete  loss  of  rods  and  a  marked  increase  in  S-cones,
demonstrating a phenotype similar to that in human ESCS and
mouse rd7. In these mice, no rod function or rod-specific gene
is expressed (even during early retinal development), and no
NR2E3  transcripts  are  found,  suggesting  that  NR2E3  is
downstream of NRL in the transcription hierarchy [14].
It is possible that in our analysis of the NR2E3 gene a
mutation  in  this  gene,  although  looked  for,  was  missed.
However,  the  unique  phenotype  seen  in  the  two  brothers
implies the presence of another mutation, namely one that
results in enhanced S-cone function together with normal rod
function.  One  possibility  is  that  another  protein,  as  yet
unknown,  imposes  negative  inhibition,  perhaps  in  a  step
upstream of NR2E3, on the embryonic development of rod
and S-cones. This finding suggests that NR2E3 mutations
prohibit the development of photoreceptor precursors to the
rod  and  L-  and  M-cones,  causing  ESCS  in  upstream
embryogenesis. The S-cone normally develops from a pre-
precursor that develops in turn into the former photoreceptor
precursor and S-cones. It is possible that our two patients
harbor a new mutation that causes the photoreceptor precursor
to differentiate into rods and not L- and M-cones. The NRL
protein, which was found to be located upstream of the NR2E3
protein [14], is probably not far enough upstream to cause this
new  phenotype.  Further  investigation  will  be  needed  to
identify the specific mutation causing this phenotype.
In summary, we present evidence that a genetic defect in
a gene other than NRL or NR2E2 causes a new autosomal
recessive clinical phenotype of enhanced S-cone activity with
normal b-wave amplitude rod function. Identification of this
mutation  is  a  prerequisite  for  understanding  the  factors
regulating  photoreceptor  development.  This  in  turn  is
essential for gaining a better understanding of photoreceptor
development when looking for factors promoting stem cells
for retinal therapy in the future.
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